10-Q · May 11, 2026
For Q1 2026, ArriVent BioPharma reported a net loss of $43.3 million, an improvement from a loss of $64.4 million in Q1 2025, although no revenue was generated for the quarter, consistent with previous periods.…
Earnings analysis · 10-Q
AVBP earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
ArriVent’s Q2 2026 loss widened to $1.05 per diluted share from $0.96 in Q1 2026 and $0.90 in Q2 2025, while operating expenses reached $52.7 million. The company reported $373.1 million of cash and investments as of…
Read full summary
ArriVent’s Q2 2026 loss widened to $1.05 per diluted share from $0.96 in Q1 2026 and $0.90 in Q2 2025, while operating expenses reached $52.7 million. The company reported $373.1 million of cash and investments as of June 30, 2026 and expects that balance to fund operations into 2028, with key firmonertinib and ARR-002 milestones expected in 2026. Sentiment is bearish on the worsening loss trend and the newly disclosed USPTO reexamination of the RE ’687 Patent, despite the extended runway and upcoming clinical catalysts.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.05
What stood out
-
Quarterly loss widened
Diluted EPS was a loss of $1.05 in Q2 2026, widening from a $0.96 loss in Q1 2026 and a $0.90 loss in Q2 2025.
-
Pipeline spending remains elevated
Operating expenses increased to $52.7 million in Q2 2026, reflecting continued investment in the clinical-stage pipeline.
-
Cash runway extends into 2028
Cash and investments totaled $373.1 million as of June 30, 2026, which management expects to fund operations into 2028.
-
Multiple 2026 pipeline milestones
Management expects topline firmonertinib Phase 3 data in the second half of 2026 and ARR-002 first-patient dosing in Q3 2026.
-
No material inflation impact
The company reported no material effect from inflation during the periods presented and does not anticipate a material impact going forward.
What to watch
-
Firmonertinib patent reexamination
On July 22, 2026, the USPTO granted an anonymous third party’s request for ex parte reexamination of U.S. Reissue Patent No. 48,687, which covers firmonertinib-related compounds. The proceeding could confirm, narrow, or cancel claims, potentially affecting the company’s patent protection and prospects.
-
Ongoing losses and cash burn
The company remains loss-making, reporting a $1.05 diluted EPS loss in Q2 2026 and $52.7 million of operating expenses. Continued clinical development spending increases dependence on the reported $373.1 million cash-and-investments balance and successful pipeline execution.
-
IP litigation and resource diversion
The company stated that legal proceedings can create defense and settlement costs and divert management resources; the RE ’687 Patent reexamination could result in claims being cancelled or narrowed, although the company believes the request lacks merit.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash and investments of $373.1 million as of June 30, 2026 are expected to fund operations into 2028; topline firmonertinib Phase 3 data are expected in the second half of 2026 and ARR-002 first-patient dosing is expected in Q3 2026.
Earlier filings 4
10-Q · November 10, 2025
Arrivent reported no revenue and a wider quarterly loss as it ramped development spending: net loss for the three months ended September 30, 2025 was $(34,978) compared with $(20,564) a year earlier, and diluted net…
10-Q · May 12, 2025
Arrivent BioPharma reported a sharp step-up in operating activity in 2025 Q1 driven by research and development spending: R&D expense rose to $61,289 (three months ended March 31, 2025) from $16,975 in the year-ago…
10-Q · May 8, 2024
Arrivent reported a Q1 net loss of $17.4M (operating loss $20.7M) on no revenue, with R&D spending rising to $16.975M from $10.236M a year earlier. The company materially strengthened its liquidity via its January IPO…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.